<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00044512</url>
  </required_header>
  <id_info>
    <org_study_id>10874</org_study_id>
    <nct_id>NCT00044512</nct_id>
    <nct_alias>NCT00048919</nct_alias>
    <nct_alias>NCT00058383</nct_alias>
  </id_info>
  <brief_title>A Study to Estimate Safety and Efficacy of Sorafenib (BAY43-9006) in the Treatment of Hepatocellular Carcinoma</brief_title>
  <official_title>A Phase II Multicenter Uncontrolled Trial of Sorafenib (BAY43-9006) in Patients With Advanced Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate anti-cancer activity (e.g. proportion of patients with confirmed complete response
      or partial response) in patients with advanced, inoperable biopsy-proven hepatocellular
      carcinoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In addition to the key secondary outcome parameters the following exploratory parameters were
      evaluated in subpopulations:

        -  Pharmacokinetics (PK) profile of Sorafenib

        -  Plasma and tissue tumor biomarkers
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2002</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants for Each Type of Response</measure>
    <time_frame>Until 30 days after termination of active therapy</time_frame>
    <description>Objective response rate of sorafenib assessed as the proportion of subjects with confirmed complete or partial response as per modified World Health Organization (WHO) criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>up to 3 years later</time_frame>
    <description>Duration of response was calculated from the first drug treatment date until documented progressive disease (PD). PD was 1) 25% or more increase in the sum of all target lesion areas taking as reference the smallest sum recorded at or following baseline, 2) unequivocal progression of an existing non-target lesion, or 3) appearance of a new lesion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response</measure>
    <time_frame>up to 3 years later</time_frame>
    <description>Time from the first day of receiving study drug to the date the CR or PR was documented (with confirmation).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression</measure>
    <time_frame>up to 3 years later</time_frame>
    <description>Time from the first date of receiving study drug until the first documented PD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Stable Disease</measure>
    <time_frame>up to 3 years later</time_frame>
    <description>Time from the first day of receiving study drug until there was a documented PD or response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Minor Response</measure>
    <time_frame>up to 3 years later</time_frame>
    <description>Time from the first day of receiving study drug to the date the MR was first documented (with confirmation). Minor response = &gt;25% regression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Minor Response</measure>
    <time_frame>Time from MR to PD</time_frame>
    <description>Time from the date that MR was first documented to the date that PD was first documented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Start of treatment to death</time_frame>
    <description>Time from the first date of receiving study medication to death.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">137</enrollment>
  <condition>Carcinoma, Hepatocellular</condition>
  <arm_group>
    <arm_group_label>Sorafenib 400 mg b.i.d.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sorafenib (Nexavar, BAY43-9006) 400 mg administered bis in die (bid, twice a day)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib (Nexavar, BAY43-9006)</intervention_name>
    <description>Sorafenib (Nexavar, BAY43-9006) 400 mg administered bis in die (bid, twice a day)</description>
    <arm_group_label>Sorafenib 400 mg b.i.d.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed primary hepatocellular carcinoma (HCC)

          -  Inoperable disease (T2-T4, any N, M0 or M1) or refused surgery

          -  Measurable disease

          -  At least 1 bidimensionally measurable lesion of at least 2 cm by computed tomography
             (CT) scan or magnetic resonance imaging (MRI)

          -  Presence of at least 1 of the following:

          -  Alpha-fetoprotein greater than the upper limit of normal (ULN)

          -  Hepatitis C antibody positive

          -  Hepatitis B surface antigen positive

          -  Child's Pugh class A or B

          -  Candidate for systemic therapy

        Exclusion Criteria:

          -  Fibrolamellar disease mixed histology

          -  Metastatic brain or meningeal tumors
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021-6007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bruxelles - Brussel</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bruxelles - Brussel</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bruxelles - Brussel</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lille Cedex</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rennes Cedex</city>
        <zip>35062</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Petach Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rehovot</city>
        <zip>76100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tel Hashomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rozzano</city>
        <state>Milano</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Forl√¨</city>
        <zip>47100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pisa</city>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Verona</city>
        <zip>37126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <results_reference>
    <citation>Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De Greve J, Douillard JY, Lathia C, Schwartz B, Taylor I, Moscovici M, Saltz LB. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006 Sep 10;24(26):4293-300. Epub 2006 Aug 14.</citation>
    <PMID>16908937</PMID>
  </results_reference>
  <results_reference>
    <citation>Abou-Alfa GK, Amadori D, Santoro A, Figer A, De Greve J, Lathia C, Voliotis D, Anderson S, Moscovici M, Ricci S. Safety and Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh A versus B Cirrhosis. Gastrointest Cancer Res. 2011 Mar;4(2):40-4.</citation>
    <PMID>21673874</PMID>
  </results_reference>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 30, 2002</study_first_submitted>
  <study_first_submitted_qc>September 3, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 4, 2002</study_first_posted>
  <results_first_submitted>February 20, 2009</results_first_submitted>
  <results_first_submitted_qc>June 19, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 6, 2009</results_first_posted>
  <last_update_submitted>March 26, 2014</last_update_submitted>
  <last_update_submitted_qc>March 26, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>Liver Cancer</keyword>
  <keyword>Hepatocellular carcinoma (HCC)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Only subjects with measurable, histologically or cytologically documented hepatocellur carcinoma (HCC) which was inoperable or who had refused surgery could participate in this study.</recruitment_details>
      <pre_assignment_details>Of 147 enrolled patients, 137 received treatment. 10 patients failed screening; reasons were: target lesions identified at baseline (3), liver function tests too high for inclusion (2), prior systemic anticancer treatment (2), creatinine too high for inclusion (1), platelets too low for inclusion (1), diagnosis of HCC not confirmed (1)</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sorafenib 400 mg b.i.d.</title>
          <description>Sorafenib (Nexavar, BAY43-9006) 400 mg administered bis in die (bid, twice a day)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="137"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="137"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Follow Up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="137"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="135"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sorafenib 400 mg b.i.d.</title>
          <description>Sorafenib (Nexavar, BAY43-9006) 400 mg administered bis in die (bid, twice a day)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="137"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Child Pugh Status</title>
          <description>A Child-Pugh (CP) score (determined by encephalopathy grade, ascites, serum bilirubin and albumin, prothrombin time) is used to assess the prognosis of chronic liver disease, mainly cirrhosis. One of the inclusion criterion for this study was a CP class A (good operative risk) or B (moderate risk) score; class C (poor operative risk) was excluded.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Status A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Status B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Eastern Cooperative Group performance status (ECOG PS) at study entry</title>
          <description>Eastern Cooperative Oncology Group (ECOG) Performance Status is a scale that measures how cancer affects a patient. 0 = fully active, 1 = restricted strenuous activity, 2 = ambulatory, 3 = limited selfcare, 4 = completely disabled, 5 = dead. Subjects entering this study must have had an ECOG score of 0 or 1.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Grade 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Stage of Disease at study entry (TNM Classification)</title>
          <description>TNM (Tumor, Nodes, Metastasis) is a solid tumor classification system. T1-T4 = size and degree of spreading. N0-N3 = degree of spreading into lymph nodes. M0-M1 = whether the cancer has metastazied beyond the lymph nodes or not. Bigger numbers are worse. One of the inclusion criteria for this study was inoperable tumor T2-T4, any N, M0 or M1.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Stage 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stage 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stage 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stage 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants for Each Type of Response</title>
        <description>Objective response rate of sorafenib assessed as the proportion of subjects with confirmed complete or partial response as per modified World Health Organization (WHO) criteria.</description>
        <time_frame>Until 30 days after termination of active therapy</time_frame>
        <population>Intention to Treat (ITT) analyses were performed on subgroups of patients categorized by baseline characteristics of ECOG Performance Status, Child Pugh status, TNM stage at study entry, prior surgical procedure, hepatitis A and B status, and age.</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib 400 mg b.i.d.</title>
            <description>Sorafenib (Nexavar, BAY43-9006) 400 mg administered bis in die (bid, twice a day)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants for Each Type of Response</title>
          <description>Objective response rate of sorafenib assessed as the proportion of subjects with confirmed complete or partial response as per modified World Health Organization (WHO) criteria.</description>
          <population>Intention to Treat (ITT) analyses were performed on subgroups of patients categorized by baseline characteristics of ECOG Performance Status, Child Pugh status, TNM stage at study entry, prior surgical procedure, hepatitis A and B status, and age.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete response (CR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial response (PR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minor response (MR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable disease (SD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive disease (PD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not available for independent review (NA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not evaluable (NE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response</title>
        <description>Duration of response was calculated from the first drug treatment date until documented progressive disease (PD). PD was 1) 25% or more increase in the sum of all target lesion areas taking as reference the smallest sum recorded at or following baseline, 2) unequivocal progression of an existing non-target lesion, or 3) appearance of a new lesion.</description>
        <time_frame>up to 3 years later</time_frame>
        <population>Intention to Treat (ITT) analyses were performed on all treated subjects and for subgroups baseline Child Pugh status (A vs B), ECOG PS (0 vs 1), TNM stage at study entry (II/III vs IV), hepatitis B and C status (positive vs negative). The 3 subjects are censored at time of evaluation. The Median is not estimable so the reported number is biased.</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib 400 mg b.i.d.</title>
            <description>Sorafenib (Nexavar, BAY43-9006) 400 mg administered bis in die (bid, twice a day)</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response</title>
          <description>Duration of response was calculated from the first drug treatment date until documented progressive disease (PD). PD was 1) 25% or more increase in the sum of all target lesion areas taking as reference the smallest sum recorded at or following baseline, 2) unequivocal progression of an existing non-target lesion, or 3) appearance of a new lesion.</description>
          <population>Intention to Treat (ITT) analyses were performed on all treated subjects and for subgroups baseline Child Pugh status (A vs B), ECOG PS (0 vs 1), TNM stage at study entry (II/III vs IV), hepatitis B and C status (positive vs negative). The 3 subjects are censored at time of evaluation. The Median is not estimable so the reported number is biased.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="374" lower_limit="369" upper_limit="443"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Response</title>
        <description>Time from the first day of receiving study drug to the date the CR or PR was documented (with confirmation).</description>
        <time_frame>up to 3 years later</time_frame>
        <population>Intention to Treat (ITT) analyses were performed on all treated subjects and for subgroups such as baseline Child Pugh status (A vs B), ECOG PS (0 vs 1), TNM stage at study entry (II/III vs IV), hepatitis B and hepatitis C status (positive vs negative).</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib 400 mg b.i.d.</title>
            <description>Sorafenib (Nexavar, BAY43-9006) 400 mg administered bis in die (bid, twice a day)</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Response</title>
          <description>Time from the first day of receiving study drug to the date the CR or PR was documented (with confirmation).</description>
          <population>Intention to Treat (ITT) analyses were performed on all treated subjects and for subgroups such as baseline Child Pugh status (A vs B), ECOG PS (0 vs 1), TNM stage at study entry (II/III vs IV), hepatitis B and hepatitis C status (positive vs negative).</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144" lower_limit="109" upper_limit="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Progression</title>
        <description>Time from the first date of receiving study drug until the first documented PD.</description>
        <time_frame>up to 3 years later</time_frame>
        <population>Intention to Treat (ITT) analyses were performed on all treated subjects and for subgroups such as baseline Child Pugh status (A vs B), ECOG PS (0 vs 1), TNM stage at study entry (II/III vs IV), hepatitis B and hepatitis C status (positive vs negative).</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib 400 mg b.i.d.</title>
            <description>Sorafenib (Nexavar, BAY43-9006) 400 mg administered bis in die (bid, twice a day)</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Progression</title>
          <description>Time from the first date of receiving study drug until the first documented PD.</description>
          <population>Intention to Treat (ITT) analyses were performed on all treated subjects and for subgroups such as baseline Child Pugh status (A vs B), ECOG PS (0 vs 1), TNM stage at study entry (II/III vs IV), hepatitis B and hepatitis C status (positive vs negative).</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="167" lower_limit="140" upper_limit="284"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Stable Disease</title>
        <description>Time from the first day of receiving study drug until there was a documented PD or response.</description>
        <time_frame>up to 3 years later</time_frame>
        <population>Intention to Treat (ITT) analyses were performed on all treated subjects and for subgroups such as baseline Child Pugh status (A vs B), ECOG PS (0 vs 1), TNM stage at study entry (II/III vs IV), hepatitis B and hepatitis C status (positive vs negative).</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib 400 mg b.i.d.</title>
            <description>Sorafenib (Nexavar, BAY43-9006) 400 mg administered bis in die (bid, twice a day)</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Stable Disease</title>
          <description>Time from the first day of receiving study drug until there was a documented PD or response.</description>
          <population>Intention to Treat (ITT) analyses were performed on all treated subjects and for subgroups such as baseline Child Pugh status (A vs B), ECOG PS (0 vs 1), TNM stage at study entry (II/III vs IV), hepatitis B and hepatitis C status (positive vs negative).</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="166" lower_limit="135" upper_limit="275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Minor Response</title>
        <description>Time from the first day of receiving study drug to the date the MR was first documented (with confirmation). Minor response = &gt;25% regression.</description>
        <time_frame>up to 3 years later</time_frame>
        <population>Intention to Treat (ITT) analyses were performed on all treated subjects and for subgroups such as baseline Child Pugh status (A vs B), ECOG PS (0 vs 1), TNM stage at study entry (II/III vs IV), hepatitis B and hepatitis C status (positive vs negative).</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib 400 mg b.i.d.</title>
            <description>Sorafenib (Nexavar, BAY43-9006) 400 mg administered bis in die (bid, twice a day)</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Minor Response</title>
          <description>Time from the first day of receiving study drug to the date the MR was first documented (with confirmation). Minor response = &gt;25% regression.</description>
          <population>Intention to Treat (ITT) analyses were performed on all treated subjects and for subgroups such as baseline Child Pugh status (A vs B), ECOG PS (0 vs 1), TNM stage at study entry (II/III vs IV), hepatitis B and hepatitis C status (positive vs negative).</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84" lower_limit="54" upper_limit="168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Minor Response</title>
        <description>Time from the date that MR was first documented to the date that PD was first documented.</description>
        <time_frame>Time from MR to PD</time_frame>
        <population>Intention to Treat (ITT) analyses were performed on all treated subjects and for subgroups such as baseline Child Pugh status (A vs B), ECOG PS (0 vs 1), TNM stage at study entry (II/III vs IV), hepatitis B and hepatitis C status (positive vs negative).</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib 400 mg b.i.d.</title>
            <description>Sorafenib (Nexavar, BAY43-9006) 400 mg administered bis in die (bid, twice a day)</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Minor Response</title>
          <description>Time from the date that MR was first documented to the date that PD was first documented.</description>
          <population>Intention to Treat (ITT) analyses were performed on all treated subjects and for subgroups such as baseline Child Pugh status (A vs B), ECOG PS (0 vs 1), TNM stage at study entry (II/III vs IV), hepatitis B and hepatitis C status (positive vs negative).</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122" lower_limit="49" upper_limit="222"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Time from the first date of receiving study medication to death.</description>
        <time_frame>Start of treatment to death</time_frame>
        <population>Intention to Treat (ITT) analyses were performed on all treated subjects and for subgroups such as baseline Child Pugh status (A vs B), ECOG PS (0 vs 1), TNM stage at study entry (II/III vs IV), hepatitis B and hepatitis C status (positive vs negative).</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib 400 mg b.i.d.</title>
            <description>Sorafenib (Nexavar, BAY43-9006) 400 mg administered bis in die (bid, twice a day)</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Time from the first date of receiving study medication to death.</description>
          <population>Intention to Treat (ITT) analyses were performed on all treated subjects and for subgroups such as baseline Child Pugh status (A vs B), ECOG PS (0 vs 1), TNM stage at study entry (II/III vs IV), hepatitis B and hepatitis C status (positive vs negative).</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="280" lower_limit="212" upper_limit="340"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Acronyms in Adverse Event section: Gastrointestinal (GI), Central Nervous System (CNS), Not Otherwise Specified (NOS), Absolute Neutrophil Count (ANC), Alanine Transaminase (ALT), Aspartate Transaminase (AST), Gamma Glutamyl Transpeptidase (GGT), Acute Respiratory Distress Syndrome (ARDS), Without grade 3 or 4 (W/O GR 3 or 4), Neutropenia (Neu)</desc>
      <group_list>
        <group group_id="E1">
          <title>Sorafenib 400 mg b.i.d.</title>
          <description>Sorafenib (Nexavar, BAY43-9006) 400 mg administered b.i.d.&quot;Other AE&quot; section includes SAEs</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>NCI CTC 2.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutrophils</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Lymphatics - Other (Specify)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Supraventricular Arrythmia, Sinus Bradicardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Supraventricular Arrythmia, Supraventricular Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Cardiac Ischemia / Infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Cardiac General - Other (Specify)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>GI - Other (Specify)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Proctitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Constitutional Symptoms - Other (Specify)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Pain, Abdomen NOS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Pain - Other (Specify)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Alkaline Phospharase</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>AST</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinemia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Liver Dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>GGT increase</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Hepatobiliary - Other (Specify)</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection W/GR 3 or GR 4 Neu</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Infection without Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Infection - Other (Specify)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Amylase</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Lipase</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal - Other (Specify)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CNS Ischemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Memory Impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Neurology - Other (Specify)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Syncope (Fainting)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercreatininemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Genito-Urinary - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Urinary Retention</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ARDS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Pulmonary - Other (Specify)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Dyspnea (Shortness of Breath)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Head-Foot Skin Reaction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Wound Complication, non-infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Dermatology - Other (Specify)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Rash/Desquamation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>CNS Hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Melena / GI Bleeding</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Hemorrhage with Surgery</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Hemorrhage - Other (Specify)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Rectal Bleeding</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Hematemesis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Hemorrhage / Bleeding W/O GR 3 or GR 4 Thrombo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>NCI CTC 2.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="126" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="76" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>GI-Other</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="76" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Pain, Abdomen NOS</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Pain, Other</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Weight Loss</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Pain, Head/Headache</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Pain, Muscle</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>AST</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Bilirubin (Hyperbilirubinemia)</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Alkaline Phosphatase</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>ALT</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>GGT</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Hepatobiliary-Other</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection Without Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Amylase</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Lipase</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Metabolic/Lab-Other</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Pulmonary-Other</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Dyspnea (Shortness of Breath)</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Voice Changes</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hand-Foot Skin Reaction</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Rash/Desquamation</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Dermatology-Other</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Agreement between Sponsor and PI should be reached before publication</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Subjects had advanced disease and were heavily pretreated. National Cancer Institute-Common Toxicity Criteria (NCI-CTC) was translated to Medical Dictionary for Regulatory Activities (MedDRA) for System Organ Class (SOC) only.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Therapeutic Area Head</name_or_title>
      <organization>BAYER</organization>
      <email>clinical-trials-contact@bayerhealthcare.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

